Chai Discovery, Supported by OpenAI, Achieves $1.3 Billion Valuation: CEO Claims 'Five-Year Challenges' Resolved in Just Weeks

Funding and Valuation: Chai Discovery, an OpenAI-backed biotech startup, has raised $130 million in a Series B funding round, increasing its valuation to $1.3 billion and bringing its total capital raised to over $225 million.

Board Expansion: The funding round was led by General Catalyst and Oak HC/FT, with notable participation from various investors, and resulted in the addition of Annie Lamont and Hemant Taneja to Chai's board of directors.

AI-Driven Drug Design: Founded in 2024, Chai Discovery focuses on AI models like Chai 2 to predict molecular interactions and design custom antibodies, significantly accelerating drug design processes.

Future Plans: The company intends to utilize the new funds to enhance research and product development while expanding its commercialization efforts in the biotech sector.